Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy

Tumori

Volumn 97, Issue 5, 2011, Pages 590-595

  Lee, Shin Wha ^a   Park, Sang Min ^a   Kim, Yong Man ^a   Kim, Young Seok ^a   Choi, Eun Kyung ^a   Kim, Dae Yeon ^a   Kim, Jong Hyeok ^a   Nam, Joo Hyun ^a   Kim, Young Tak ^a  

^a University of Ulsan   (South Korea)

Author keywords

Prognostic factor; Radiation therapy; Recurrent epithelial ovarian cancer; Regression rate; Survival

Indexed keywords

PLATINUM COMPLEX;

ABDOMINAL WALL; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL OVARIAN CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INJURY SEVERITY; LYMPH NODE; OUTCOME ASSESSMENT; OVARY ADENOCARCINOMA; OVARY CANCER; PELVIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RADIATION RESPONSE; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 83055170764     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700509     Document Type: Article

References (29)

1. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C,NardiM, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. JNatlCancer Inst, 92: 699-708, 2000.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med, 334: 1-6, 1996. (Pubitemid 26012496)
3. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB,Wheeler S, Swart AM, QianW, TorriV, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR- 2.2 trial. Lancet, 361: 2099-2106, 2003.
4. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA,Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol, 15: 987-993, 1997. (Pubitemid 27106281)
5. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ: Phase II study of intravenous topotecan as a 5- day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol, 14: 1552-1557, 1996. (Pubitemid 26134213)
6. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 19: 3312-3322, 2001. (Pubitemid 32642183)
7. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L,Varette C, RipocheV, Kayitalire L: A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol, 9: 1343-1345, 1998. (Pubitemid 29045575)
8. Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, Jones W, Lewis JL Jr, Almadrones L, HoskinsW: Phase 2 trial of chronic lowdose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol, 119: 55-57, 1992.
9. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: Screening, treatment, and follow-up. JAMA, 273: 491-497, 1995.
10. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant ovarian cancer. J Clin Oncol, 12: 60-63, 1994. (Pubitemid 24020621)
11. Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol, 10: 243-248, 1992.
12. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B: Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group Ancillary Report. Gynecol Oncol, 62: 4-6, 1996. (Pubitemid 26234538)
13. Markman M, Blessing JA, Moore D, Ball H, Lentz SS: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol, 69: 226-229, 1998. (Pubitemid 28289964)
14. Thigpen JT, Vance RB, Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer, 71: 559- 564, 1993.
15. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol, 12: 1748-1753, 1994. (Pubitemid 24349373)
16. Vergote I, Himmelmann A, Frankendal B, Scheistrøen M, Vlachos K, Tropé C: Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol, 47: 282-286, 1992. (Pubitemid 23011405)
17. Hodson DI, Krepart GV: Once-monthly radiotherapy for the palliation of pelvic gynecological malignancy. Gynecol Oncol, 16: 112-116, 1983. (Pubitemid 13041654)
18. Adelson MD, Wharton JT, Delclos L, Copeland L, Gershenson D: Palliative radiotherapy for ovarian cancer. Int J Radiat Oncol Biol Phys, 13: 17-21, 1987. (Pubitemid 17023442)
19. May LF, Belinson JL, Roland TA: Palliative benefit of radiation therapy in advanced ovarian cancer. Gynecol Oncol, 37: 408-411, 1990. (Pubitemid 20182991)
20. Davidson SA, Rubin SC, Mychalczak B, Saigo PE, Lewis JL Jr, Chapman D, Hoskins WJ: Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer. Gynecol Oncol, 51: 349-354, 1993. (Pubitemid 24058610)
21. Corn BW, Lanciano RM, Boente M, Hunter WM, Ladazack J, Ozols RF: Recurrent ovarian cancer: effective radiotherapeutic palliation after chemotherapy failure. Cancer, 74: 2979-2983, 1994. (Pubitemid 24361084)
22. Gelblum D, Mychalczak B, Almadrones L, Spriggs D, Barakat R: Palliative benefit of external beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol Oncol, 69: 36-41, 1998. (Pubitemid 28201669)
23. Firat S, Erickson B: Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum. Gynecol Oncol, 80: 213-220, 2001. (Pubitemid 32158461)
24. Tinger A, Waldron T, Peluso N, Katin MJ, Dosoretz DE, Blitzer PH, Rubenstein JH, Garton GR, Nakfoor BA, Patrice SJ, Chuang L, Orr JW Jr: Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys, 51: 1256-1263, 2001. (Pubitemid 33116319)
25. Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I: Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. Int J Gynecol Cancer, 12: 250-256, 2002. (Pubitemid 34787551)
26. Bae J, Lim MC, Choi JH, Song YJ, Lee KS, Kang S, Seo SS, Park SY: Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol, 20: 101-106, 2009.
27. Cmelak AJ, Kapp DS: Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer. Gynecol Oncol, 65: 453-460, 1997. (Pubitemid 27255988)
28. Fuks Z, Rizel S, Biran S: Chemotherapeutic and surgical inductionofpathological complete remissionandwhole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. J Clin Oncol, 6: 509-516, 1988. (Pubitemid 18090700)
29. Choan E, Quon M, Gallant V, Samant R: Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. Gynecol Oncol, 102: 204-209, 2006. (Pubitemid 44056257)